vs
Pacira BioSciences, Inc.（PCRX）与Purple Innovation, Inc.（PRPL）财务数据对比。点击上方公司名可切换其他公司
Pacira BioSciences, Inc.的季度营收约是Purple Innovation, Inc.的1.3倍（$177.4M vs $140.7M），Pacira BioSciences, Inc.净利率更高（1.6% vs -2.3%，领先3.9%），Purple Innovation, Inc.同比增速更快（9.1% vs 5.0%），过去两年Purple Innovation, Inc.的营收复合增速更高（8.3% vs -0.2%）
Pacira BioSciences是一家专科制药企业，专注于非阿片类疼痛管理药物的研发与商业化，核心产品线面向术后镇痛场景，服务以美国为主的医院、门诊手术中心等医疗服务机构，同时推进部分国际市场的拓展工作。
Purple Carrot是一家总部位于马萨诸塞州尼达姆市的全植物性餐包品牌，由安迪·莱维特创立，每周为订阅用户提供预制餐品和自制餐包。据《大都会》2022年报道，对比美式标准餐食，该品牌每份餐包的碳排放量可降低72%，主打低碳环保的纯植物饮食方案。
PCRX vs PRPL — 直观对比
营收规模更大
PCRX
是对方的1.3倍
$140.7M
营收增速更快
PRPL
高出4.1%
5.0%
净利率更高
PCRX
高出3.9%
-2.3%
两年增速更快
PRPL
近两年复合增速
-0.2%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $177.4M | $140.7M |
| 净利润 | $2.9M | $-3.2M |
| 毛利率 | — | 41.9% |
| 营业利润率 | 3.9% | -1.6% |
| 净利率 | 1.6% | -2.3% |
| 营收同比 | 5.0% | 9.1% |
| 净利润同比 | — | 62.1% |
| 每股收益（稀释后） | $0.07 | $0.03 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收PCRXPRPL
| Q1 26 | $177.4M | — | ||
| Q4 25 | $196.9M | $140.7M | ||
| Q3 25 | $179.5M | $118.8M | ||
| Q2 25 | $181.1M | $105.1M | ||
| Q1 25 | $168.9M | $104.2M | ||
| Q4 24 | $187.3M | $129.0M | ||
| Q3 24 | $168.6M | $118.6M | ||
| Q2 24 | $178.0M | $120.3M |
净利润PCRXPRPL
| Q1 26 | $2.9M | — | ||
| Q4 25 | — | $-3.2M | ||
| Q3 25 | $5.4M | $-11.7M | ||
| Q2 25 | $-4.8M | $-17.3M | ||
| Q1 25 | $4.8M | $-19.1M | ||
| Q4 24 | — | $-8.5M | ||
| Q3 24 | $-143.5M | $-39.2M | ||
| Q2 24 | $18.9M | $27.0K |
毛利率PCRXPRPL
| Q1 26 | — | — | ||
| Q4 25 | 79.5% | 41.9% | ||
| Q3 25 | 80.9% | 42.8% | ||
| Q2 25 | 77.4% | 35.9% | ||
| Q1 25 | 79.7% | 39.4% | ||
| Q4 24 | 78.7% | 42.9% | ||
| Q3 24 | 76.9% | 29.7% | ||
| Q2 24 | 75.1% | 40.7% |
营业利润率PCRXPRPL
| Q1 26 | 3.9% | — | ||
| Q4 25 | 1.2% | -1.6% | ||
| Q3 25 | 3.5% | -10.2% | ||
| Q2 25 | 4.7% | -13.5% | ||
| Q1 25 | 1.2% | -13.9% | ||
| Q4 24 | 13.2% | -6.0% | ||
| Q3 24 | -82.8% | -39.5% | ||
| Q2 24 | 15.9% | -12.1% |
净利率PCRXPRPL
| Q1 26 | 1.6% | — | ||
| Q4 25 | — | -2.3% | ||
| Q3 25 | 3.0% | -9.9% | ||
| Q2 25 | -2.7% | -16.5% | ||
| Q1 25 | 2.8% | -18.4% | ||
| Q4 24 | — | -6.6% | ||
| Q3 24 | -85.1% | -33.1% | ||
| Q2 24 | 10.6% | 0.0% |
每股收益（稀释后）PCRXPRPL
| Q1 26 | $0.07 | — | ||
| Q4 25 | $0.05 | $0.03 | ||
| Q3 25 | $0.12 | $0.11 | ||
| Q2 25 | $-0.11 | $0.16 | ||
| Q1 25 | $0.10 | $0.18 | ||
| Q4 24 | $0.38 | $0.08 | ||
| Q3 24 | $-3.11 | $0.36 | ||
| Q2 24 | $0.39 | $0.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $144.3M | $24.3M |
| 总债务越低越好 | — | $126.7M |
| 股东权益账面价值 | $653.9M | $-29.7M |
| 总资产 | $1.2B | $296.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资PCRXPRPL
| Q1 26 | $144.3M | — | ||
| Q4 25 | $238.4M | $24.3M | ||
| Q3 25 | $246.3M | $32.4M | ||
| Q2 25 | $445.9M | $34.2M | ||
| Q1 25 | $493.6M | $21.6M | ||
| Q4 24 | $484.6M | $29.0M | ||
| Q3 24 | $453.8M | $23.4M | ||
| Q2 24 | $404.2M | $23.4M |
总债务PCRXPRPL
| Q1 26 | — | — | ||
| Q4 25 | $372.2M | $126.7M | ||
| Q3 25 | $376.7M | — | ||
| Q2 25 | $580.5M | — | ||
| Q1 25 | $583.4M | — | ||
| Q4 24 | $585.3M | $70.7M | ||
| Q3 24 | — | $50.8M | ||
| Q2 24 | — | — |
股东权益PCRXPRPL
| Q1 26 | $653.9M | — | ||
| Q4 25 | $693.1M | $-29.7M | ||
| Q3 25 | $727.2M | $-26.9M | ||
| Q2 25 | $757.8M | $-15.6M | ||
| Q1 25 | $798.5M | $1.3M | ||
| Q4 24 | $778.3M | $20.2M | ||
| Q3 24 | $749.6M | $28.0M | ||
| Q2 24 | $879.3M | $66.4M |
总资产PCRXPRPL
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.3B | $296.3M | ||
| Q3 25 | $1.3B | $302.1M | ||
| Q2 25 | $1.5B | $303.8M | ||
| Q1 25 | $1.6B | $293.8M | ||
| Q4 24 | $1.6B | $307.8M | ||
| Q3 24 | $1.5B | $309.3M | ||
| Q2 24 | $1.6B | $362.1M |
负债/权益比PCRXPRPL
| Q1 26 | — | — | ||
| Q4 25 | 0.54× | — | ||
| Q3 25 | 0.52× | — | ||
| Q2 25 | 0.77× | — | ||
| Q1 25 | 0.73× | — | ||
| Q4 24 | 0.75× | 3.50× | ||
| Q3 24 | — | 1.82× | ||
| Q2 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $-5.8M |
| 自由现金流经营现金流 - 资本支出 | — | $-7.8M |
| 自由现金流率自由现金流/营收 | — | -5.5% |
| 资本支出强度资本支出/营收 | — | 1.4% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-41.9M |
8季度趋势，按日历期对齐
经营现金流PCRXPRPL
| Q1 26 | — | — | ||
| Q4 25 | $43.7M | $-5.8M | ||
| Q3 25 | $60.8M | $-968.0K | ||
| Q2 25 | $12.0M | $-4.0M | ||
| Q1 25 | $35.5M | $-23.1M | ||
| Q4 24 | $33.1M | $6.8M | ||
| Q3 24 | $53.9M | $1.1M | ||
| Q2 24 | $53.2M | $-8.9M |
自由现金流PCRXPRPL
| Q1 26 | — | — | ||
| Q4 25 | $43.5M | $-7.8M | ||
| Q3 25 | $57.0M | $-1.8M | ||
| Q2 25 | $9.3M | $-7.0M | ||
| Q1 25 | $26.9M | $-25.3M | ||
| Q4 24 | $31.0M | $5.7M | ||
| Q3 24 | $49.8M | $101.0K | ||
| Q2 24 | $51.6M | $-11.0M |
自由现金流率PCRXPRPL
| Q1 26 | — | — | ||
| Q4 25 | 22.1% | -5.5% | ||
| Q3 25 | 31.7% | -1.5% | ||
| Q2 25 | 5.1% | -6.6% | ||
| Q1 25 | 15.9% | -24.3% | ||
| Q4 24 | 16.6% | 4.4% | ||
| Q3 24 | 29.6% | 0.1% | ||
| Q2 24 | 29.0% | -9.2% |
资本支出强度PCRXPRPL
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | 1.4% | ||
| Q3 25 | 2.2% | 0.7% | ||
| Q2 25 | 1.5% | 2.8% | ||
| Q1 25 | 5.1% | 2.2% | ||
| Q4 24 | 1.1% | 0.8% | ||
| Q3 24 | 2.4% | 0.9% | ||
| Q2 24 | 0.9% | 1.7% |
现金转化率PCRXPRPL
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 11.20× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 7.37× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2.82× | -330.22× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
PRPL
| Cost Of Revenues | $81.7M | 58% |
| Other | $59.0M | 42% |
